NANTKWEST INC. DL-,0001 Forum: Community User: Ibt2

Ich dachte wir wären hier bei Nantkwest, was hat das mit anderen Unternehmen zu tun. Verstehe ich nicht.

2,73 Dollar wohlgemerkt 😁

Man hast du ne Langeweile, warten wir bis die KE bei Medigene kommt, dann weinst du wieder und bist noch weiter von deinen 11,xx entfernt.

Aber er bleibt drauf hocken, dass ist nicht fair........😁😂🤣

Wirklich sauber !!

Alles richtig gemacht............😁

Schmidtskatze 👍

Phase 2 Studie mit ImmunityBio zur Bekämpfung von Bauchspeicheldrüsenkrebs wird schon im Juni starten. Für mich das Wichtigste: Der Patient, welcher mit PD-L1 t-haNK und N-803 gegen Bauchspeicheldrüsenkrebs behandelt wurde, ist auch 6 Monate nach der Behandlung immer noch Krebsfrei. Wenn dieser Erfolg reproduziert werden kann, dann ist das eine Sensation und für den Aktienkurs gibt es dann nur noch eine Richtung.

Da sind die Neuigkeiten: NantKwest and ImmunityBio to Initiate a Phase 2 Study of Immunotherapy for Metastatic Pancreatic Cancer Open-label, randomized Phase 2 study will evaluate combination immunotherapy, including NantKwest’s PD-L1 tumor-targeted natural killer cells and ImmunityBio’s IL-15 superagonist N-803 with standard of care versus standard of care alone Metastatic pancreatic cancer patient treated with PD-L1 t-haNK and N-803 through a single patient IND has ongoing, durable, complete response six months after initial treatment The study has received FDA authorization and is expected to begin in June 2020 May 14, 2020 04:25 PM Eastern Daylight Time EL SEGUNDO, Calif.--(BUSINESS WIRE)--NantKwest, Inc. (Nasdaq: NK), a clinical-stage, natural killer cell-based therapeutics company, and ImmunityBio, a privately-held immunotherapy company, today announced plans for a Phase 2, randomized, open-label study to evaluate the efficacy and safety of their combination immunotherapy: NantKwest’s PD-L1 t-haNK, ImmunityBio’s N-803, and aldoxorubicin HCI plus standard of care, versus standard-of-care chemotherapy for first- and second-line treatment of locally advanced or metastatic pancreatic cancer. “Our results from expanded access use of PD-L1 t-haNK in combination with N-803 offer proof-of-concept that, together with these agents, the immune system may play a role to activate robust and durable responses in metastatic cancer patients who have failed all standard-of-care therapies” Four metastatic pancreatic cancer patients have been treated with PD-L1 t-haNK and N-803 under single patient INDs, with two patients on treatment for an evaluable period. One patient reported ongoing, durable, complete response six months after treatment, and one observed response of stable disease. The Investigational New Drug (IND) application has received authorization from the U.S. Food and Drug Administration (FDA) with the study anticipated to begin in June 2020. “Our results from expanded access use of PD-L1 t-haNK in combination with N-803 offer proof-of-concept that, together with these agents, the immune system may play a role to activate robust and durable responses in metastatic cancer patients who have failed all standard-of-care therapies,” said Patrick Soon-Shiong, M.D., Chairman and Chief Executive Officer of NantKwest and ImmunityBio. “Based on these encouraging data, we are moving forward with a randomized Phase 2 program that will evaluate our immunotherapy combination on top of standard of care, compared to standard of care alone, in first- and second-line treatment settings. This unique approach to orchestrating the innate and adaptive immune systems to induce immunogenic cell death may be an important new approach for pancreatic cancer patients—these being among the most challenging to treat with poor prognoses.” “Abraxane, a protein-based nanoparticle that activates macrophages, was our first evolution in making an impact on pancreatic cancer. With this addition of PD-L1 t-haNK and N-803, we are hopeful that we can proceed to the next step of long-term remission in this difficult to treat disease. Adding a natural killer cell with a checkpoint via PD-L1 t-haNK and activating memory T cells via N-803 will complete the ‘triangle offense’ we are orchestrating. The early results of complete response in one patient using the therapy on a compassionate use basis is encouraging and we are excited to initiate this trial involving other patients who suffer from pancreatic cancer,” he said. Study Details: This Phase 2, randomized, two-cohort, open-label study will evaluate the comparative efficacy and overall safety of standard-of-care chemotherapy versus standard-of-care chemotherapy in combination with PD-L1 t-haNK, N-803, and aldoxorubicin HCl in subjects with locally advanced or metastatic pancreatic cancer (QUILT-88). Each treatment setting, and first- and second-line or later maintenance, will be evaluated independently as Cohort A and Cohort B, respectively, with each Cohort having independent experimental and control arms. The study will initially enroll 268 subjects across both cohorts with the primary objective of comparative efficacy by progression free survival (PFS) per RECIST V1.1. Secondary objectives include initial safety and additional efficacy measures, including overall response rate (ORR), complete response (CR) rate, durability of response (DoR), disease control rate (DCR), and overall survival (OS). Pancreatic cancer kills an estimated 47,000 people annually; it is the fourth leading cause of cancer-related death in the U.S., and 57,600 new cases are expected in 2020. Less than 5% of these patients will live for more than five years after diagnosis, and the median survival prognosis is 5 to 8 months.

Nach MEZ hat die Konferenz um 9:20Uhr angefangen. Hoffentlich hat Patrick Soon Shiong neue Investoren überzeugt und vielleicht kommen im Laufe des Tages noch Neuigkeiten zu der Pipeline und der Covid-19 Forschung ans Taheslicht.

Mal gucken ob es morgen etwas Neues gibt, bin gespannt.: EL SEGUNDO, Calif., April 29, 2020 – NantKwest, Inc. (NASDAQ: NK) and ImmunityBio, Inc., today announced that Patrick Soon-Shiong, M.D., Chairman and CEO of both companies, will present at the virtual Bank of America Merrill Lynch Global Healthcare Conference on May 14, 2020 at 4:20pm E.T. Dr. Soon-Shiong will present a clinical pipeline update with registrational strategies for NantKwest’s off-the-shelf natural killer cell-based therapeutics in combination with ImmunityBio’s N-803 Interleukin 15 (IL-15) ‘superagonist’ cytokine. He will also provide an update on the companies’ COVID-19 therapeutic and vaccine candidates.

Aber Glückwunsch Schmidtskatze, für den Augenblick war das ein guter Trade, sehr gut abgepasst. Zu wieviel bist du raus?

Hält sich prima, nach dem krassen Anstieg gestern. Volumen passt auch mit über 900.000Stk.

Gewinne mitgenommen. Ist mir zu undurchsichtig 🤔

Obwohl Covid 19 Durchbruch ansich unmöglich ist, da man erst vor sehr kurzer Zeit mit der Forschung begonnen hat.